Roche's return to RNA continues with $1.7B deal for Sanegene program
Roche's return to RNA continues with $1.7B deal for Sanegene program
Body unavailable. Use the original source.
Roche's return to RNA continues with $1.7B deal for Sanegene program
A compact weekly email covering company moves, product signals, regulatory updates, and notable funding.